Craig-Hallum analyst Alexander Nowak maintained a Buy rating on ProSomnus (OSA – Research Report) today. The company’s shares closed last Friday at $5.03.
Nowak covers the Healthcare sector, focusing on stocks such as CVRx, NeoGenomics, and REPRO-MED Systems. According to TipRanks, Nowak has an average return of -5.7% and a 39.20% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ProSomnus with a $9.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $11.30 and a one-year low of $4.57. Currently, ProSomnus has an average volume of 7,409.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lakeshore Acquisition I Corp is a blank check company. Its objective is to acquire, through a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.
Read More on OSA:
- ProSomnus management to meet with Oppenheimer
- Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
- ProSomnus initiated with a Buy at Roth MKM
- ProSomnus receives U.S. utility patent covering iterative titration technology
- ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices
